Human Immunodeficiency Viruses (HIV) Clinical Trials Market Outlook 2025–2029: Regional Growth and Sizing Insights

 Get 30% Off Market Intelligence Reports With Code ONLINE30 — Track Global Tariffs, Economic Shifts, and Sector Transformations

 

 What Is the Growth Potential of the Human Immunodeficiency Viruses (HIV) Clinical Trials Market in the Next Decade?
 The human immunodeficiency viruses (HIV) clinical trials market size has grown strongly in recent years. It will grow from $1.77 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing prevalence of drug-resistant human immunodeficiency viruses strains, rising demand for personalized medicine in human immunodeficiency viruses care, growing emphasis on early diagnosis and treatment, increasing number of clinical research organizations, and rising awareness of human immunodeficiency viruses-related comorbidities.
 
 The human immunodeficiency viruses (HIV) clinical trials market size is expected to see strong growth in the next few years. It will grow to $2.73 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to increasing prevalence of human immunodeficiency viruses infections, rising awareness about human immunodeficiency viruses prevention and treatment, growing adoption of antiretroviral therapy, increasing government funding and support for human immunodeficiency viruses research, and growing investment in biotechnology and pharmaceuticals. Major trends in the forecast period include technology-driven innovations in hiv diagnostics, advancements in antiretroviral therapy (art) formulations, developments in biomarker identification, technology-enabled remote monitoring tools, and integration of digital health platforms.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28244&type=smp
 
 What Are the Key Drivers of the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
 The increasing incidence of human immunodeficiency virus (HIV) infections is expected to propel the growth of the human immunodeficiency virus (HIV) clinical trials market going forward. Human immunodeficiency virus (HIV) infections refer to the condition caused by the HIV virus attacking and weakening the immune system, increasing susceptibility to infections and potentially leading to AIDS. The increase in HIV infections is largely due to lack of awareness about transmission, resulting to risky behaviors and delayed testing that facilitate the virus’s spread. Human immunodeficiency virus (HIV) clinical trials help patients suffering from HIV infections by testing new drugs, vaccines, and treatment strategies to improve prevention, manage the virus more effectively, and ultimately reduce disease progression and transmission. For instance, in August 2024, according to the Minority HIV/AIDS Fund (MHAF), a US-based government agency, an estimated 39.9 million individuals worldwide were living with HIV in 2023, consisting of 38.6 million adults and 1.4 million children, compared to previous years. Therefore, the increasing incidence of human immunodeficiency virus (HIV) infections is driving the growth of the human immunodeficiency virus (HIV) clinical trials market.
 
 How Is the Human Immunodeficiency Viruses (HIV) Clinical Trials Market Divided by Type and Application?
 The human immunodeficiency viruses (HIV) clinical trials market covered in this report is segmented as
 
 1) By Phase: Phase I, Phase II, Phase III, Phase IV, Preclinical
 2) By Drug Type: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs
 3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
 4) By Patient Population: Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations
 5) By End User: Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users
 
 Subsegments:
 1) By Phase I: First-In-Human Studies, Safety And Tolerability Studies
 2) By Phase Ii: Dose-Finding Studies, Efficacy Studies
 3) By Phase Iii: Pivotal Trials, Comparative Efficacy Studies
 4) By Phase Iv: Post-Marketing Surveillance, Long-Term Safety Studies
 5) By Preclinical: In Vitro Studies, Animal Studies
 
 Which Emerging Trends Are Driving the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
 Major companies operating in the human immunodeficiency virus (HIV) clinical trials market are focusing on developing innovative solutions such as HIV prevention injections to enhance treatment efficacy and reduce transmission rates. An HIV prevention injection refers to a long-acting injectable medication administered periodically to prevent HIV infection in high-risk individuals by blocking the virus from establishing infection in the body. For instance, in August 2025, Gilead Sciences Inc., a US-based pharmaceutical company, received an approval from the European Union for Yeytuo (lenacapavir) to treat HIV. It is a twice-yearly injectable HIV prevention treatment that offers high efficacy, nearly 100% in clinical trials, significantly reducing the risk of sexually acquired HIV-1 infection. Its long-acting dosing improves adherence and convenience compared to daily oral PrEP, addressing a major gap in HIV prevention. This is designed for adults and adolescents at increased risk, that aims to expand access and help reduce new HIV infections globally as part of comprehensive prevention strategies.
 
 What Are the Top Companies to Watch in the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
 Major companies operating in the human immunodeficiency viruses (hiv) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio.
 
 Get the full human immunodeficiency viruses (hiv) clinical trials market report here:
 https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-viruses-hiv-clinical-trials-global-market-report
 
 How Does Human Immunodeficiency Viruses (HIV) Clinical Trials Market Growth Vary Across Major Regions?
 North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human immunodeficiency virus (HIV) clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company